It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for all-cause mortality (11 studies, I2=89%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for ACVD-related events (13 studies, I2=75%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
It is very uncertain whether higher dose changes deaths compared with lower dose (very low certainty).
It is very uncertain whether higher dose changes intermediate syndrome compared with lower dose (very low certainty).
It is very uncertain whether higher dose changes ventilated compared with lower dose (very low certainty).
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).